Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...
Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company developing immunotherapies, has announced promising results from its Phase 1b study of azer-cel, an off-the-shelf, allogeneic CAR T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results